COVID-19 Treatment 'Paxlovid' Administered in Daegu Starting from the 14th

Priority Supply for Home Treatment and Living Treatment Center Residents... Asymptomatic Patients Excluded from Medication

Oral COVID-19 treatment Paxlovid. / Photo by Jinhyung Kang aymsdream@

[Asia Economy Yeongnam Reporting Headquarters, Reporter Yeo Jong-gu] Daegu city health authorities announced on the 14th that they have started prescribing the oral COVID-19 treatment Paxlovid.

This treatment was supplied in 365 doses (215 for home treatment, 150 for residential treatment centers), and will be administered immediately when eligible patients arise.

Paxlovid is primarily given to mild to moderate patients at high risk of progressing to severe illness within 5 days of symptom onset, prioritizing those aged 65 or older or immunocompromised individuals receiving home treatment or admitted to residential treatment centers. Asymptomatic patients are excluded from treatment.

Home treatment patients receive telemedicine consultations from designated medical institutions in Daegu, including Daegu Medical Center, Chilgok Kyungpook National University Hospital, Keimyung University Daegu Dongsan Hospital, and Hanyoung Hanmaeum Children's Hospital, and then receive the treatment through designated pharmacies and public health centers.

Patients admitted to residential treatment centers are administered the medication by dedicated medical staff, who conduct daily telephone monitoring of patients taking the medication.

Even if symptoms improve during the course of the oral treatment, patients must complete the prescribed dosage and regimen, taking 3 tablets twice a day for 5 days.

Additionally, patients taking contraindicated medications or those with kidney or liver impairments have restrictions or prohibitions on receiving the treatment.

Lee Young-hee, Director of the Daegu City Citizen Health Bureau, stated, “On the 12th, eight district and county public health centers, four designated medical institutions, and eight dedicated pharmacies completed joint practice for prescribing and delivering the oral treatment,” adding, “We hope the oral treatment will reduce the proportion of severe COVID-19 cases.”

This content was produced with the assistance of AI translation services.